

Omit ALK and ROS1

Non-Ewing Sarcoma NGS Fusion Panel

□ NTRK NGS Fusion Panel (NTRK 1-3)

# **New York State NGS Solid Tumor Pathology Requisition**

🗖 PM

Rev. 101623

Client Information		Patient Information		
Required Information         Account #:          Street Address:          City, ST, ZIP:		First Name:	<b>☐ Male ☐ Female</b> Other Pt ID/Acct #:	
Phone: Fax:		By completing this section, Clien	t represents it has obtained informed consent from patient to perform the	
Additional Reporting Fax:		services described herein.		
Requisition Completed by:		<b>Specimen Information</b>	on	
Ordering Physician (please print: Last, First):		Specimen ID:	Block ID:	
Treating Physician (please print: Last, First):		Fixative/Preservative:		
The undersigned certifies that he/she is licensed to order the test(s) listed b medically necessary for the care/treatment of this patient.	elow and that such test(s) are		/ dd / yyyy Collection Time: AM D PM	
Authorized Signature:	Date:	Retrieved Date: mm / Hospital Discharge Date: mm Body Site:	/ dd / yyyy	
Billing Information			Metastasis, list Primary:	
Required: Please include face sheet and front/back of patient's primary         Patient Status (Must Choose 1):        Hospital Patient (in)          Bill to:        Client Bill        Insurance          Medicare        Me         Split Billing - Client (TC) and Insurance (PC)        OP Molecular         Bill charges to other Hospital/Facility:	nt (out) INon-Hospital Patient dicaid Patient/Self-Pay to MCR, all other testing to Client	Fresh Tissue (Media Type rec     Fluid: CSF Ple     FNA cell block:     Smears: Air Dried     Slides # Unst	(s) Purple Top(s) Other quired): eural Other Fixed Stained (type of stain) tained Stained □ H&E □ Choose best block (for global molecular/NGS testing only)	
Clinical Information			Submit ≤4 blocks. Blocks will be combined for molecular testing when necessary.	
Required: Please attach patient's pathology report (required), clinical history, and other applicable report(s).		For all other testing, specify which block to use for each if sending multiple blocks. See back for details. Predictive Marker Fixation (CAP/ASCO Requirement): *Indicated markers/profiles/panels require fixation information		
Reason for Referral: New Diagnosis Relapse In Remission Monitoring			□ ≤ 1 hour □ Unknown er: □ Unknown	
Staging: 0 0 1 0 11 0 111 0 111A 0 111B 0 IV N	ote:	Fixation duration (hours):	🖬 6-72 hours 🗖 Unknown	
NeoTYPE <sup>®</sup> Cancer Profiles <sup>‡</sup> *Reflex to NTRK 1-3 FISH Panel instead of NTRK NGS if Pan-TRK IHC is p			G - Global TF - Tech-Only FISH TI - Tech-Only IHC	
G TF TI <sup>***</sup> N/A Brain (DNA & RNA) Add MGMT Promoter Methylation Analysis Breast Tumor Profile* Cervical Tumor Profile* Colorectal Tumor Profile* C	G       TF       TI***         □       □       Gastric Tumor Profile*         □       □       GI Predictive Profile*         □       □       Perform HER2 IHC with reflex         □       HER2 (Other) w/Gastric S       Reflex to HER2 (Other) w/         if global HER2 IHC is □       □         □       Do Not Reflex 2+         □       HER2 Gastric/GEA         •       Reflex to HER2 Gastric/GEA	coring FISH (Default) Gastric Scoring FISH <b>G T</b> 1+ 2+ (Default) 3+ A (FISH) <b>G T</b> if 1+ 2+ (Default) 3+	G TF TI**      Ovarian Tumor Profile*     Opt out of HER2 IHC □ Opt out of FOLR1 IHC     Reflex to HER2 (Other) w/Breast Scoring FISH □ G □ T     if global HER2 IHC is □ 0 □ 1+ □ 2+ (Default) □ 3+     □ Do Not Reflex 2+     Pancreas Tumor Profile* □ Opt out of HER2 IHC     Reflex to HER2 (Other) w/Breast Scoring FISH □ G □ T     if global HER2 IHC is □ 0 □ 1+ □ 2+ (Default) □ 3+     □ Do Not Reflex 2+     N/A □ Precision Profile*     One Not Reflex 2+     N/A □ Precision Profile*     Ordering Pathologist listed has received the required competency training to     perform the professional interpretation for PD-L1. Please contact Client Services for Lung options.	
RNA-Based NGS Fusion Panels		Unknown or Uncertain Tumor Type		
Brain NGS Fusion Panel       NTRK & RET NGS Fusion Panel         Breast NGS Fusion Panel       Prostate NGS Fusion Panel         Cholangio/Pancreatic Carcinoma NGS Fusion Panel       Rhabdomyosarcoma NGS Fusion         Colorectal NGS Fusion Panel       Salivary Gland NGS Fusion		CancerTYPE ID <sup>®</sup> with reflex to NeoTYPE <sup>®</sup> Cancer Profile     Tumor classification, followed by targeted biomarkers based on CancerTYPE ID result     NeoTYPE <sup>®</sup> is global unless marked: □ Tech-Only FISH □ Tech-Only IHC***		
	Sarcoma Comprehensive NGS Fusion Panel	Other Testing		
Lung NGS Fusion Panel (ALK, MET, NRG1, NTRK1-3, RET, ROS1)			BRCA1/2 Mutation Analysis for Tumors RAS/RAF Panel	

For our complete test menu, TAT, specimen requirements and more, please visit **neogenomics.com**.

□ Thyroid NGS Fusion Panel

Universal Solid Tumor NGS Fusion Panel

G Т D Other

Breast Cancer Index® (BCI): separate requisitions required, see website.

# **Specimen Requirements.**

Refrigerate specimen if not shipping immediately and use cool pack during transport. Please call Client Services team with any questions regarding specimen requirements or shipping instructions at 866.776.5907 option 1. Please refer to the website for specific details on each specimen.

## **Additional Billing Information**

Any organization referring specimens for testing services pursuant to this Requisition Form ("Client") expressly agrees to the following terms and conditions.

- 1. Binding Service Order. This Requisition Form is a contractually binding order for the services ordered hereunder ("Services") and Client agrees that it is financially responsible for all tests billable to Client hereunder.
- 2. Third Party Billing by NeoGenomics and Right to Bill Client. Client agrees to accurately indicate on the front of the Requisition Form that either Client should be billed (e.g., Client receives reimbursement pursuant to a non-fee-for-service basis, including, but not limited to, a capitated, diagnostic related group ("DRG"), per diem, all-inclusive, or other such bundled or consolidated billing arrangement) or NeoGenomics should bill the applicable federal, state or commercial health insurer or other third party payer (collectively, "Payers") for all Services ordered pursuant to this Requisition Form. For all such Services billable to Payers, Client agrees to provide all billing information necessary for NeoGenomics to bill such payer. In the event NeoGenomics: (i) does not receive the billing information required for it to bill any Payers within ten days of the date that any Services are reported by NeoGenomics; (ii) the Services were performed for patients who have no Payer coverage arrangements; or (iii) the Payer identified by Client denies financial responsibility for the Services and indicates that Client is financially responsible, NeoGenomics shall have the right to bill such Services to Client.

#### **Additional Specimen Information**

If submitting multiple blocks, client must indicate either "Choose best block (global molecular/NGS testing only)" or assign the selection of blocks to individual tests. If multiple blocks are sent without a selection, they will be held until clarification is provided. Please call Client Services Team with any questions regarding specimen information.

## **Test Descriptions**

Please see complete test descriptions and all available tests at our website, www.neogenomics.com/test-menu.

## **Test Notations**

#### Specimen Usage

NeoGenomics makes every effort to preserve and not exhaust tissue, but in small and thin specimens, there is a possibility of exhausting the specimen in order to ensure adequate material and reliable results.

## NeoTYPE® DNA & RNA Profile - Brain

If the sample is insufficient to produce both DNA and RNA results, the available results will be reported and alternate CPT<sup>®</sup> Codes may apply. Please see website for details.

## CancerTYPE ID® with reflex to NeoTYPE® Cancer Profile

The specific NeoTYPE Cancer Profile added is determined by the CancerTYPE ID result. See www.neogenomics.com for test details.

CancerTYPE ID will be performed, reported and billed separately by Biotheranostics, Inc. For comprehensive details about CancerTYPE ID including test description, intended use, and limitations, visit www.cancertypeid.com.

For our complete test menu, TAT, specimen requirements and more, please visit: www.neogenomics.com